Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?

Am J Respir Crit Care Med. 2003 Mar 15;167(6):809-10. doi: 10.1164/rccm.2301002.
No abstract available

Publication types

  • Editorial
  • Review
  • Comment

MeSH terms

  • Antibiotics, Antitubercular / adverse effects*
  • Antibiotics, Antitubercular / economics
  • Antitubercular Agents / adverse effects*
  • Antitubercular Agents / economics
  • Chemical and Drug Induced Liver Injury / diagnosis
  • Chemical and Drug Induced Liver Injury / etiology
  • Chemical and Drug Induced Liver Injury / metabolism
  • Drug Costs
  • Drug Therapy, Combination
  • HIV Infections / complications
  • Humans
  • Liver Function Tests
  • Patient Compliance
  • Patient Selection*
  • Practice Guidelines as Topic
  • Pyrazinamide / adverse effects*
  • Pyrazinamide / economics
  • Rifampin / adverse effects*
  • Rifampin / economics
  • Risk Factors
  • Safety*
  • Tuberculin Test
  • Tuberculosis / diagnosis
  • Tuberculosis / drug therapy*

Substances

  • Antibiotics, Antitubercular
  • Antitubercular Agents
  • Pyrazinamide
  • Rifampin